238 related articles for article (PubMed ID: 2148245)
1. [Response of estrogen and progesterone receptors to treatment with large doses of progestogen (depo-provera) in endometrial cancer].
Thurzó L
Zentralbl Gynakol; 1990; 112(17):1111-5. PubMed ID: 2148245
[TBL] [Abstract][Full Text] [Related]
2. [Estrogen and progesterone receptors in endometrial carcinoma during high-dose progestogen (Depo-Provera) therapy].
Thurzó L; Sas M; Falkay G
Orv Hetil; 1986 Oct; 127(43):2613-6. PubMed ID: 2947029
[No Abstract] [Full Text] [Related]
3. [Surface changes in endometrial cancer under the effect of large doses of progestogen (Depo-Provera)].
Szarvas Z; Zsolnai B
Morphol Igazsagugyi Orv Sz; 1984 Apr; 24(2):92-9. PubMed ID: 6717452
[No Abstract] [Full Text] [Related]
4. Effect of progestogen (Depo-Provera) on annulate lamellae in endometrial carcinoma.
Szarvas Z; Zsolnai B
Acta Chir Hung; 1984; 25(4):269-76. PubMed ID: 6240879
[TBL] [Abstract][Full Text] [Related]
5. Hormone-resistant endometriosis following total abdominal hysterectomy and bilateral salpingo-oophorectomy: correlation with histology and steroid receptor content.
Metzger DA; Lessey BA; Soper JT; McCarty KS; Haney AF
Obstet Gynecol; 1991 Nov; 78(5 Pt 2):946-50. PubMed ID: 1833687
[TBL] [Abstract][Full Text] [Related]
6. [Effect of long-term high-dose progesterone (Depo-Provera) therapy on endometrial carcinoma].
Szarvas Z; Zsolnai B; Gimes G; Hidvégi J
Morphol Igazsagugyi Orv Sz; 1985 Oct; 25(4):253-60. PubMed ID: 2933583
[No Abstract] [Full Text] [Related]
7. [Growth of endometrial cancer and hormone].
Kanoh H; Hosono T; Matsui Y; Okudaira Y
Gan To Kagaku Ryoho; 1989 Dec; 16(12):3696-703. PubMed ID: 2531993
[TBL] [Abstract][Full Text] [Related]
8. [Progestogen therapy in the treatment of endometrial cancer--clinical results and mechanism of steroid action].
Okada H
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):924-8. PubMed ID: 2968780
[TBL] [Abstract][Full Text] [Related]
9. [Progesterone receptors in endometrial carcinoma and their response to medroxyprogesterone acetate].
Feng YJ; Zhang XY
Zhonghua Fu Chan Ke Za Zhi; 1989 May; 24(3):153-5, 189. PubMed ID: 2530067
[TBL] [Abstract][Full Text] [Related]
10. [OEstradiol and progesterone steroid hormone receptors in cancer of the endometrium. The significance of the progesterone receptor (author's transl)].
Martin PM; Rolland PH; Gammerre M; Serment H
J Gynecol Obstet Biol Reprod (Paris); 1979; 8(8):681-4. PubMed ID: 553927
[TBL] [Abstract][Full Text] [Related]
11. [Cell surface changes after high-dosage progesterone treatment in endometrial carcinoma].
Szarvas Z; Zsolnai B
Zentralbl Gynakol; 1984; 106(14):1010-7. PubMed ID: 6239468
[TBL] [Abstract][Full Text] [Related]
12. [Therapy of advanced endometrial cancer].
Okada H; Yamamoto T
Gan To Kagaku Ryoho; 1990 Sep; 17(9):1848-55. PubMed ID: 2144105
[TBL] [Abstract][Full Text] [Related]
13. Short-term effects of tamoxifen, medroxyprogesterone acetate, and their combination on receptor kinetics and 17 beta-hydroxysteroid dehydrogenase in human endometrium.
Neumannová M; Kauppila A; Kivinen S; Vihko R
Obstet Gynecol; 1985 Nov; 66(5):695-700. PubMed ID: 2997680
[TBL] [Abstract][Full Text] [Related]
14. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M
Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103
[TBL] [Abstract][Full Text] [Related]
15. Changes in receptor status after treatment with tamoxifen in endometrial cancer.
Oriana S; Raspagliesi F; Duca PG; Coradini D; Di Re EM; Ragazzi D; Grillo T; Luciani L
Int J Biol Markers; 1988; 3(4):233-6. PubMed ID: 3235850
[TBL] [Abstract][Full Text] [Related]
16. Morphology of human uterine cancer in nude mice. Effects of hormone and antihormone treatment.
Zaino RJ; Satyaswaroop PG; Mortel R
Arch Pathol Lab Med; 1984 Jul; 108(7):571-8. PubMed ID: 6547322
[TBL] [Abstract][Full Text] [Related]
17. Steroid hormone receptors and response to high-dose medroxyprogesterone acetate in advanced breast cancer.
Nomura Y; Tashiro H; Hisamatsu K; Shinozuka K
Anticancer Res; 1988; 8(4):647-51. PubMed ID: 2972248
[TBL] [Abstract][Full Text] [Related]
18. Reply to Dr. Edwin B. McDaniel. Exaggerated claims of depo-provera safety.
Minkin SF
Women Health; 1981; 6(1-2):125-9. PubMed ID: 6223451
[TBL] [Abstract][Full Text] [Related]
19. Modalities and results of a combined anti-estrogenic therapy by means of tamoxifen and medroxyprogesterone in gynecologic cancerology.
Bonte J; Janssens JP; Ide P
Eur J Gynaecol Oncol; 1986; 7(1):45-50. PubMed ID: 2938955
[TBL] [Abstract][Full Text] [Related]
20. Hormone steroid receptor variation after tamoxifen administration in endometrial adenocarcinoma from postmenopausal patients.
Di Fronzo G; Ronchi E; Cappelletti V; Luciani L; Coradini D; Oriana S; Miodini P; Andreola S
Cancer Detect Prev; 1986; 9(3-4):323-30. PubMed ID: 3742507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
